Details of the Drug

General Information of Drug (ID: DMO2K0J)

Drug Name

Pyridoxal Phosphate

Synonyms

Pyridoxal phosphate; pyridoxal phosphate; Codecarboxylase; pyridoxal 5-phosphate; 54-47-7; pyridoxal 5'-phosphate; Pyridoxal P; Pyromijin; Hairoxal; Vitazechs; Biosechs; Pyridoxal-5'-phosphate; Hiadelon; Pidopidon; Himitan; Phosphopyridoxal; Sechvitan; Pydoxal; Piodel; Pyridoxyl phosphate; Apolon B6; (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate; HI-Pyridoxin; Pal-P; PYRIDOXAL-5-PHOSPHATE; pyridoxal-P; Phosphopyridoxal coenzyme; Vitahexin P; Hexermin P; Coenzyme B6; Pyridoxal monophosphate; Pyridoxaldehyde phosphate; Apolon B(sub 6); Biosechs; PLP; Pyrido; Phosphoridoxal coenzyme; Pyridoxal phosphate [JAN]; SRI 2392; VITAMIN B6 COMPLEX; Vitamin B6 phosphate; Hexermin-P; Pyridoxal 5-monophosphoric acid ester; Pyridoxal 5-phosphate; Pyridoxal phosphate (6CI); Pyridoxal-5P; Pyridoxal-P; Sechvitan, Vitahexin P; Vitahexin-P; Vitamin B6 phosphate (ester); Pyridoxal 5'-phosphate; Pyridoxal 5'-phosphate hydrate; Pyridoxal-5-Phosphate Hydrate; Pyridoxal-5-monophosphate; P-5'-P; Pyridoxal 5'-(dihydrogen phosphate); Pyridoxal 5'-phosphate monohydrate, vitamin B6; Pyridoxal 5'-phosphate monohydrate-Vitamin B6; Pyridoxal phosphate treated beta-lactoglobulin from bovine whey; Pyridoxal, 5-(dihydrogen phosphate); Pyridoxal, 5-(dihydrogenphosphate); Pyridoxal, 5-(dihydrogen phosphate) (8CI); Phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl) ester; Isonicotinaldehyde, 3-hydroxy-5-(hydroxymethyl)-2-methyl-, 5-(dihydrogen phosphate); (4-Formyl-5-hydroxy-6-methyl(3-pyridyl))methyl dihydrogen phosphate; (4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate trihydrate; 2-Methyl-3-hydroxy-4-formyl-5-pyridylmethylphosphoric acid; 3-Hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde; 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate; 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; 4-Formyl-5-hydroxy-6-methyl-pyridin-3-yl)methoxyphosphonic acid; 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-(9CI); Lepirudine

Indication

Disease Entry	ICD 11	Status	REF
Malnutrition	5B50-5B71	Approved	[1], [2]

Therapeutic Class

Dietary supplement

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

247.14

Topological Polar Surface Area (xlogp)

-1.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C8H10NO6P
IUPAC Name: (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate
Canonical SMILES: CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O
InChI: InChI=1S/C8H10NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H2,12,13,14)
InChIKey: NGVDGCNFYWLIFO-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 1051
ChEBI ID: CHEBI:18405
CAS Number: 54-47-7
DrugBank ID: DB00114
TTD ID: D06JGH

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[3]
GABA transaminase (ABAT)	TTT2LD9	GABT_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5249).
2	Drug information of Pyridoxal Phosphate, 2008. eduDrugs.
3	New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
4	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
5	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6	Clinical pipeline report, company report or official report of Catalyst Pharma.
7	Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
8	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
9	Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
10	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11	Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
12	New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
13	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
14	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
15	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
17	Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
18	Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
19	Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
20	Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.